Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
not me...I have a much higher target...been here a while too...not as long as others but a while
yes I know but fortunately I did buy a few thousands at some cheap prices just wish there were a few thousand more.....
woo hoo!!! of course I am kicking myself for not buying even more when it was sub .05. Great news!~!!!
closed out app yesterday at 1.38 for 3.5% gain. closed out chrs at 3.55 for 5% loss.
in 3000 at 1.33
PPC looking good today
limit order partially filled on FBC at 1.40 got in at 1.25 I wish the rest were picked up sitll holding 1550. sold 450
fcel up 23% today!
just went positive on CHRS...another long hold...will keep a little longer....
i keep watching.....when they start increasing cash flow from operations...i am interested....
fcel...kicking butt.... could have gotten another 20%
missed my limit sell order on FBC by one cent... limit to sell at 1.38
waiting and watching volume
waiting and watching volume
what do you think if an entry now at 1.25???
need to get the bid up and over 1.30. In at 1.25 from this AM
Out of FCEL with a 10% gainer....that was a hold and a half
this is a nice run....
Mass. wins biotech tax credits
Boston Business Journal - by Julie M. Donnelly
Date: Tuesday, November 2, 2010, 1:50pm EDT - Last Modified: Wednesday, November 3, 2010, 6:00am EDT
A large number of Massachusetts biotechnology companies have been awarded federal tax credits as part of the Therapeutic Discovery Tax Credit program that was established within the federal health reform law approved in March.
“The Therapeutic Discovery Tax Credit ensures Massachusetts’ most cutting-edge companies will be able to maintain their commitment to investment in life-saving research,” said Robert K. Coughlin, President & CEO of MassBio, wrote in an email. “The program helps biotech companies continue to discover new cures and therapies to solve unmet medical needs, while adding good jobs across the Commonwealth. We are thrilled to see this investment being made and congratulate all of the recipients.”
Each grant, which is designed to offset up to 50 percent of qualifying research and development costs, is worth $244,479.24 to the company, and companies are eligible for more than one award. Companies must have headcount under 250, and companies meeting significant unmet medical needs will have priority. Medical device companies, as well as biotechs, are eligible. The total amount of grant money available nationwide is $1 billion.
The biggest winner appears to by Cambridge, Mass.-based Alnylam Pharmaceuticals, which won eight grants worth a total of $1,955,832. Newton, Mass.-based Celldex was awarded seven grants worth $1,711,353 in all.
Waltham-based ImmunoGen won five grants worth a total of $1,222,396.20. Cambridge, Mass.-based Momenta Pharmaceuticals, Worcester, Mass.-based RXi Pharmaceuticals, Woburn, Mass.-based ArQule and Marlborough, Mass.-based Advanced Cell Technology each won four grants worth a total of $977,917.
A number of biotechs, including Cambridge, Mass-based companies Quanterix Corporation, BIND Biosciences, Tolerx, and Ensemble Therapeutics, along with Watertown, Mass.-based companies Tetraphase Pharmaceuticals and Selecta Biosciences, all won three grants totaling $733,437.72 for each company. Cambridge, Mass.-based Helicos Biosciences also won 3 grants. Cambridge, Mass.-based biotechs bluebird bio and Concert Pharmaceuticals; Waltham, Mass.-based Avila Therapeutics, Worcester-Mass.-based SelectX Pharmaceuticals and Newton, Mass-based Pro-Pharmaceuticals, all won two grants.
Companies winning one grant each include Cambridge, Mass.-based Zalicus, Taligen Therapeutics, Constellation Pharmaceuticals, Hydra Biosciences and Semprus Biosciences; Wellesley, Mass.-based NormOxys, Lexington, Mass.-based Pulmatrix, Waltham, Mass.-based X-BODY BioSciences, South Easton-based Pressure Biosciences and Cambridge, Mass-based Ligon Discovery Inc.
The grants come at a time when many smaller biotech companies are struggling to find the cash to fund research. It will be a needed shot in the arm for companies like Pressure Biosciences, for instance, which had only $1.7 million in cash on hand as of June 30. Pro-Pharmaceuticals had cash on hand of $2.9 million as of June 30.
“We are pleased to receive these non-taxable grants from the federal government,” Theodore Zucconi, the CEO of Pro-Pharmaceuticals, said in a statement. “It was a very competitive approval process and highly oversubscribed. We believe the grants for DAVANAT®, our anti-cancer compound, and for GR-Series, our anti-fibrosis compounds, validate our drug development programs.”
The national Biotechnology Industry Organization is pushing for the program to be extended to a second year, saying it would fuel job growth in the sector.
Read more: Mass. wins biotech tax credits | Boston Business Journal
Advanced Cell Technology Receives Federal Grant for Nearly $1 Million
Advanced Cell Tech (BB) (OTCBB:ACTC)
Intraday Stock Chart
Today : Tuesday 2 November 2010
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it has received a $977,917 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The grant was related to four of the Company’s projects: the Blastomere Program, the Myoblast Program, the RPE Program for Stargardt’s Disease, and the iPS Program. The grants were for $244,479.25 each, for a total grant of $977,917.00. The funds are exempt from federal income taxes.
The PPACA provides small and mid-sized biotech, pharmaceutical and medical device companies with a tax credit for investments in qualified therapeutic discoveries for tax years 2009 and 2010, or a grant for the same amount, tax-free. The tax credit/grant program covers research and development costs from 2009 and 2010 for all qualified “therapeutic discovery projects.”
A qualifying therapeutic discovery project is one designed to diagnose, treat or prevent diseases or conditions by conducting preclinical studies or clinical trials or carrying out research protocols for the purpose of securing approval from the Food and Drug Administration. Qualifying companies must not have more than 250 employees.
“I have publicly stated that securing non-dilutive funds for our clinical programs is a priority, and securing this grant is a step toward achieving that goal,” stated William M. Caldwell IV, ACT’s Chairman and CEO. “We are particularly pleased that all four of our major research programs received funding.”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Advanced Cell Technology Receives Federal Grant for Nearly $1 Million
Advanced Cell Tech (BB) (OTCBB:ACTC)
Intraday Stock Chart
Today : Tuesday 2 November 2010
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it has received a $977,917 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA). The grant was related to four of the Company’s projects: the Blastomere Program, the Myoblast Program, the RPE Program for Stargardt’s Disease, and the iPS Program. The grants were for $244,479.25 each, for a total grant of $977,917.00. The funds are exempt from federal income taxes.
The PPACA provides small and mid-sized biotech, pharmaceutical and medical device companies with a tax credit for investments in qualified therapeutic discoveries for tax years 2009 and 2010, or a grant for the same amount, tax-free. The tax credit/grant program covers research and development costs from 2009 and 2010 for all qualified “therapeutic discovery projects.”
A qualifying therapeutic discovery project is one designed to diagnose, treat or prevent diseases or conditions by conducting preclinical studies or clinical trials or carrying out research protocols for the purpose of securing approval from the Food and Drug Administration. Qualifying companies must not have more than 250 employees.
“I have publicly stated that securing non-dilutive funds for our clinical programs is a priority, and securing this grant is a step toward achieving that goal,” stated William M. Caldwell IV, ACT’s Chairman and CEO. “We are particularly pleased that all four of our major research programs received funding.”
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
I added some 2 days ago....slowly building my position between .047 and .055....I would be happy for another 2 weeks before news
nice to see 1.07 breached on the bid
I like it. Re-Entered at 5.40 and enjoying the ride. Good company and great opportunity but lots of ups and downs to be expected. The ticker is changing to BTX on 11.02.
yep that's one....
not liking this market...nor some of my holdings....
At 1.84 its a double for me.....will have to trim....
one of us needs to sell fcel so it will go up for the other person...as I know as soon as I sell it..it will move
Looking good Billy Ray!!!
got filled on the rest of my ands....but its not moving...
nice....should have had my limit order in for 4.05 instead of 4.03....
I got a partial fill on ands ....500 @ 1.65 but won't fill the rest
did not get filled on the open for either ands or gmo....still holding fcel and chrs
i got the book on my Kindle and am enjoying it. I am scheduled to take an options class on the 27th in NYC from the OIC
now that is pretty funny....
FuelCell Energy awarded ~$2.8 mln from DoE to demonstrate the hydrogen production capacity of a Direct FuelCell power plant for an industrial user of hydrogen (FCEL) 1.23 :
and shes down 4 cents on good news...very frustrating after getting to 1.23 yesterday
I think the joint agreement with John Mauldin on the skin product has caught the attention of a lot investors....
fcel prints 1.23
same for 1.22 on fcel
I could exit at 1.20 and cover my trades tickets in and out but waiting for the pop.....